Sodium Polystyrene Sulfonate
Brand Names: Kionex, Kayexalate
Methodology & AI Transparency ⓘ
Sodium Polystyrene Sulfonate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Sodium Polystyrene Sulfonate Powder, for Suspension is indicated for the treatment of hyperkalemia.
- 2 Real-world patient consensus: 79% patient "Worth It" rating across 12 anonymous logs for Sodium Polystyrene Sulfonate (RxNorm 2101899).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $10.46 wholesale mail-order against $34.50 retail pharmacy pricing.
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Sodium Polystyrene Sulfonate include nausea (7.9%), headache (7.9%), dizziness (5.5%).
Ask our AI Specialists anything about Sodium Polystyrene Sulfonate
Sodium Polystyrene Sulfonate Mechanism, CYP450 Pathways & DailyMed Monograph
Sodium Polystyrene Sulfonate Powder, for Suspension is indicated for the treatment of hyperkalemia. Limitation of Use: Sodium Polystyrene Sulfonate Powder, for Suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action . Sodium Polystyrene Sulfonate Powder, for Suspension is indicated for the treatment of hyperkalemia (1) . Limitation of Use: Sodium Polystyrene Sulfonate Powder, for Suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action (1) .
12.1 Mechanism of Action Sodium Polystyrene Sulfonate Powder, for Suspension is a non-absorbed, cation exchange polymer that contains a sodium counterion. Sodium Polystyrene Sulfonate Powder, for Suspension increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels. The practical exchange ratio is 1 mEq K per 1 gram of resin.
With Biphasic clearance with 8–15 hr terminal t½ under Sodium Polystyrene Sulfonate maintenance residence kinetics and Systemic oral bioavailability of roughly 71%–83% following first-pass transit bioavailability, Sodium Polystyrene Sulfonate undergoes hepatic enzymatic processing and renal clearance proportional to creatinine clearance (sodium polystyrene sulfonate) and establishes therapeutic activity over initial pharmacodynamic onset within 1–3 hrs (peak cmax) for sodium polystyrene sulfonate.
Standard adult regimens span 4.1 meq/g Powder, for Suspension, 15 g/60mL Suspension, 1 g/g Powder, for Suspension, 1 g/g Powder, 60mEq Bottle of Powder. Prescribers screen specifically against sodium polystyrene sulfonate powder, for suspension is contraindicated in patients with the following conditions:; hypersensitivity to polystyrene sulfonate resins; obstructive bowel disease, while community micro-logs most frequently note nausea (7.9% of reports), headache (7.9% of reports), dizziness (5.5% of reports).
Combining Sodium Polystyrene Sulfonate with ACE inhibitors, ARBs, or aldosterone blockers can shift serum potassium and eGFR.
Avoid overlapping potassium binder prescriptions alongside Sodium Polystyrene Sulfonate to prevent cumulative receptor toxicity.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Sodium Polystyrene Sulfonate Powder, for Suspension is contraindicated in patients with the following conditions:
- Hypersensitivity to polystyrene sulfonate resins
- Obstructive bowel disease
Logged Side-Effect Incidence (12 Reports)
Sodium Polystyrene Sulfonate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sodium Polystyrene Sulfonate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of 11 sodium-glucose cotransporter-2 inhibitors at different: What a 9,144-Participant Study Found As add-on therapy, SGLT2is demonstrated favourable antidiabetic efficacy and acceptable safety. BMJ open • 2025-02-26 • Meta-Analysis | N = 9,144 | 99/100 | PMID 40010842 ↗ |
| Check Your Medicine Cabinet: FDA Enforcement Recall D-0039-2027 (Class II): Hydrocortisone Sodium Succinate for Injec Reason for recall: Failed Impurities/Degradation Specifications. openFDA Drug Enforcement & Recall Registry • 2026-10-21 • FDA Drug Recall (Class II) | Multi-cohort | 96/100 | PMID FDARECALL-D-0039-2027 ↗ |
| New Insights on Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in: What a 4,300-Participant Study Found Despite similar glycemic efficacy in a relatively short term, SGLT2 inhibitors are more effective in the longer term than SUs as add-on to metformin. Clinical drug investigation • 2019-06-15 • Meta-Analysis | N = 4,300 | 94/100 | PMID 31041606 ↗ |
| New Insights on Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or: What a 892-Participant Study Found TRK-100STP was generally well tolerated and most adverse drug reactions were mild or moderate in severity. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy • 2021-10-15 • Phase III Randomized Trial | N = 892 | 93/100 | PMID 33340238 ↗ |
| What the Latest Evidence Really Says About Benefits and safety of sodium-glucose cotransporter 2 inhibitors as add-on to Incidence of low blood sugar was significantly higher, but incidence of high blood sugar was significantly lower in SGLT2 inhibitor group. Endocrine journal • 2018-03-28 • Meta-Analysis | Multi-cohort | 92/100 | PMID 29375082 ↗ |
Sodium Polystyrene Sulfonate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1429/unit (~$4.29/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $10.46 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 12 Anonymous DotMD Community Micro-Logs | $12.03 / mo | View logs ↓ |
Sodium Polystyrene Sulfonate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Sodium Polystyrene Sulfonate RxNorm Concept ID | 2101899 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1429 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $10.46 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 79.00% Worth It (12 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Sodium Polystyrene Sulfonate Patient Community, Cohort Filters & Dosage Logs
Deterministic Sodium Polystyrene Sulfonate reference combining NIH RxNorm (2101899), Medicaid NADAC ($0.1429/unit), and anonymous cohort outcomes (79% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Sodium Polystyrene Sulfonate community threads and patient logs by age, biological sex, dosage, and treatment duration.